Nanopublication: RAVs_AYsMQ

Full identifier: http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE

Raw formats: TriG(html,txt), JSON-LD(txt), N-Quads(txt), XML(txt)

Checking for updates...

 RAVs_AYsMQ comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RAVs_AYsMQ...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) "tysabri is an integrin receptor antagonist indicated for treatment of multiple sclerosis ms tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis tysabri increases the risk of pml when initiating and continuing treatment with tysabri physicians should consider whether the expected benefit of tysabri is sufficient to offset this risk see important information regarding the risk of pml with tysabri 1 1 5 1 crohn s disease cd tysabri is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active crohn s disease with evidence of inflammation who have had an inadequate response to or are unable to tolerate conventional cd therapies and inhibitors of tnf a 1 2 important limitations in cd tysabri should not be used in combination with immunosuppressants or inhibitors of tnf a 1 2 tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis tysabri increases the risk of pml when initiating and continuing treatment with tysabri physicians should consider whether the expected benefit of tysabri is sufficient to offset this risk see important information regarding the risk of pml with tysabri see warnings and precautions 5 1 tysabri is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active crohn s disease with evidence of inflammation who have had an inadequate response to or are unable to tolerate conventional cd therapies and inhibitors of tnf a tysabri should not be used in combination with immunosuppressants e g 6 mercaptopurine azathioprine cyclosporine or methotrexate or inhibitors of tnf a see warnings and precautions 5 1" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAVs_AYsMQ... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-07-03T15:13:05.636+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAVs_AYsMQ... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RAVs_AYsMQ... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAVs_AYsMQ... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAVs_AYsMQ...#sig sig http://purl.org/nanopub/x/hasSignatureTarget has as target This is the identifier for this whole nanopublication. http://purl.org/np/RAVs_AYsMQ... this nanopublication .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAVs_AYsMQ...#sig sig http://purl.org/nanopub/x/hasAlgorithm has the algorithm (this is a literal) "RSA" .

Leoni Bücken, 3 Jul 2021, 13:13:05 UTC

show references